| Liraglutide (n = 23) | Placebo (n = 26) |
---|---|---|
Demographics | ||
 Age in years  (SD) | 60 (6) | 59 (7) |
 Male | 14 (61%) | 15 (58%) |
 Diabetes duration in years (SD) | 11 (6) | 11 (7) |
 Diabetes complications | ||
  Retinopathy, n | 4 (17%) | 2 (8%) |
  Nephropathy, n | 2 (9%) | 11 (42%) |
  Neuropathy | 10 (44%) | 7 (27%) |
  Macrovasculara | 2 (9%) | 0 (0%) |
Clinical parameters | ||
 Weight in kg (SD) | 98 (14) | 94 (13) |
 Body-mass index in kg/m2 (SD) | 32.6 (4.4) | 31.6 (3.4) |
 Systolic blood pressure in mmHg (SD) | 141 (14) | 141 (15) |
 Diastolic blood pressure in mmHg (SD) | 86 (6) | 87 (11) |
 Glycated haemoglobin A1c in % (SD) | 8.4 (1.1) | 8.2 (1.0) |
 Glycated haemoglobin A1c in mmol/mol (SD) | 67 (12) | 65 (10) |
 Serum creatinine in μmol/L (SD) | 73 (19) | 68 (17) |
 Urinary albumin/creatinine ratio in mmol/μg (SD) | 1.0 (1.3) | 5.0 (8.9) |
 Triglycerides in mmol/L (SD) | 2.2 (1.5) | 2.1 (1.1) |
 Total cholesterol in mmol/L (SD) | 4.8 (1.0) | 4.8 (1.0) |
 HDL-c in mmol/L (SD) | 1.2 (0.2) | 1.3 (0.4) |
 LDL-c in mmol/L (SD) | 2.6 (0.9) | 2.5 (0.9) |
Smoking history | ||
 Never smoked, n | 10 (44%) | 8 (31%) |
 Current smoker, n | 4 (17%) | 5 (19%) |
 Ex-smoker, n | 9 (39%) | 13 (50%) |
Concomitant drug use | ||
 Metformin dose in g/day (SD) | 2.1 (0.7) | 2.0 (0.5) |
 Sulfonylurea, n | 6 (26%) | 8 (31%) |
 Insulin, n | 15 (65%) | 17 (65%) |
 Anti-lipidaemic, n | 21 (91%) | 19 (73%) |
 Anti-hypertensive, n | 18 (78%) | 20 (77%) |
LV diastolic function | ||
 E in mL/s (SD) | 331 (99) | 325 (96) |
 A in mL/s (SD) | 367 (79) | 371 (70) |
 E/A ratio (SD) | 0.95 (0.44) | 0.90 (0.31) |
 Edec in mL/s2 × 10−3 (SD) | 2.9 (0.9) | 2.6 (1.2) |
 Ea in cm/s (SD) | 6.0 (1.6) | 6.0 (1.8) |
 E/Ea (SD) | 7.3 (2.9) | 7.9 (2.3) |
LV systolic function | ||
 Stroke volume in mL (SD) | 81 (16) | 76 (18) |
 Ejection fraction in % (SD) | 55 (5.8) | 55 (4.5) |
 Cardiac output in L/min (SD) | 5.4 (0.9) | 5.5 (1.0) |
 Cardiac index in L/min/m2 (SD) | 2.5 (0.3) | 2.6 (0.4) |
 Peak ejection rate in mL/s (SD) | 442 (96) | 415 (92) |